## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `vip-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/vip-ibd/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/vip-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/vip-ibd/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/vip-ibd/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/vip-ibd/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/vip-ibd/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `vip-ibd` v2 · content_hash `15b4fea8778d13c6…` · thread_head genesis · 22 DIVs
- **thesis (c1):** VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.
  - c3 [human/active] VIP plasma levels vary with IBD severity in a study of 115 patients.
  - c4 [human/active] VIP nerve changes observed in Crohn's rectal tissue samples.
  - c2 [preclinical/active] VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.
  - c5 [preclinical/active] VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.
  - c6 [anecdotal/active] Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/vip-ibd/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/vip-ibd/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `vip-ibd`
- **title:** VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis
- **url:** https://miscsubjects.com/a/vip-ibd
- **register:** source_ledger
- **updated:** 2026-07-17T02:43:24.692Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have IBD (Crohn's / colitis)

If your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.

## Why VIP might help you

1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.
2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.

If immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic

## What the evidence actually shows

Human data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.

Preclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduced clinical signs including weight loss, diarrhea, and histologic inflammation (source s3). VIP nanomedicine in DSS and TNBS mouse colitis lowered pro-inflammatory cytokines, improved histology, and supported tight junction proteins (source s4). VIP-deficient mice showed greater susceptibility to chemically induced colitis in some experiments, with exogenous VIP rescuing barrier features (source s5). Results are mixed across studies; some report exacerbation depending on model and microbiota (source s5).

Anecdotal data: Limited. One Reddit thread states VIP is among the better researched compounds for Crohn's via upstream immune effects on gut lining (source s6). Other posts discuss VIP in unrelated contexts such as CIRS or Raynaud's with no IBD-specific outcomes reported.

## What scientists say

Researchers note VIP's immunomodulatory properties in colitis models and suggest it as a candidate for further testing in Crohn's, while highlighting inconsistent findings in knockout models and human expression data (sources s3, s5). Emphasis remains on preclinical promise rather than clinical translation.

## What people say on Reddit

Discussions are sparse. Users mention VIP's anti-inflammatory profile and one notes specific research interest in Crohn's. No detailed personal outcome reports tied to IBD treatment appear in top results.

## What people say on X

No relevant patient experiences or outcome reports surfaced in searches for VIP in IBD contexts.

## What we do not know

No published human intervention trials test VIP administration for IBD symptom control or mucosal healing. Optimal delivery, duration, and patient selection remain untested in controlled settings. Long-term effects on human gut microbiota or barrier repair are unknown.

## Safety and limits

VIP is a naturally occurring peptide with documented effects in animal colitis models, but human safety data for therapeutic use in IBD do not exist in the reviewed sources. Observational human studies report no direct safety signals from measurement alone. All therapeutic claims rest on preclinical work.

## Claims (6)

- **c3** [human w=0.8] VIP plasma levels vary with IBD severity in a study of 115 patients.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [preclinical w=0.5] VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.
  - who_claims: grok/grok-4.3
  - sources: s4
- **c5** [preclinical w=0.5] VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c4** [human w=0.8] VIP nerve changes observed in Crohn's rectal tissue samples.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c1** [preclinical w=0.5] VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c6** [anecdotal w=0.3] Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.
  - who_claims: grok/grok-4.3
  - sources: s6

## Voxel graph (6 atoms · 12 edges)
- full graph: https://miscsubjects.com/api/articles/vip-ibd/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (6)
- chain valid: yes · head: `d7f83bf06126e68f`

### s1 · pubmed · ok
- title: Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease
- url: https://pubmed.ncbi.nlm.nih.gov/2791804/
- summary: Observational measurement of VIP in IBD patients.
- quote: One hundred-fifteen adult IBD patients were studied cross-sectionally and prospectively, 48 with ulcerative colitis (UC) and 67 with Crohn's disease (CD).
- claim_ids: c3
- hash: `fee95fb26e17ba61`

### s2 · pubmed · http_403
- title: Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease
- url: https://gut.bmj.com/content/25/1/57
- summary: Tissue findings in Crohn's patients.
- quote: Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal...
- claim_ids: c4
- hash: `d52d9ae4269ca5e8`

### s3 · pubmed · http_403
- title: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease
- url: https://www.gastrojournal.org/article/S0016-5085(03)00055-6/fulltext
- summary: Mouse TNBS colitis study showing reduced severity.
- quote: Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation.
- claim_ids: c1
- hash: `126f99982f20657e`

### s4 · pubmed · ok
- title: Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC6053281/
- summary: Nanomedicine improved inflammation and barrier markers in mouse models.
- quote: We demonstrate the therapeutic benefit of VIP-SSM over free peptide in reversing severe colitis associated with IBD.
- claim_ids: c2
- hash: `4b8b21ae33c77c99`

### s5 · pubmed · ok
- title: Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract
- url: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full
- summary: Reviews mixed preclinical and human expression data.
- quote: In some studies, VIP knockout mice were more susceptible to chemically-induced intestinal inflammation, and human inflammatory bowel disease (IBD) patients show a reduction in VIP positive nerves proximal to severe mucosal damage.
- claim_ids: c5
- hash: `ca265033e771dbdc`

### s6 · reddit · ok
- title: The peptide nobody talks about but everyone should: VIP
- url: https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/
- summary: Community comment on research relevance.
- quote: VIP is actually one of the better researched compounds for Crohn's specifically. it works upstream on the immune response in the gut lining ...
- claim_ids: c6
- hash: `d7f83bf06126e68f`

## Provenance (2 model passes)
- chain valid: yes · head: `f166b51d24870598`

- write · grok/grok-4.3 · 2026-06-29T22:29 · hash `a94782d019f0`
- voxel_divide · owner · 2026-07-17T02:43 · hash `f166b51d2487`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/vip-ibd/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/vip-ibd/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"vip-ibd","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest vip-ibd|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim vip-ibd|tier|assertion`
- **iMessage ask:** `vip-ibd|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `vip-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/vip-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/vip-ibd/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*